New report suggests rebates are not to blame for increasing drug prices

A new report by the consulting company Milliman prepared for America’s Health Insurance Plans (AHIP), suggest that drug rebates are not to blame for increases in drug prices. According to the report, rebates are typically offered only for brand-name drugs; 81 percent of all of the Medicare Part D drugs analyzed offered no rebates. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.